12/23/2024 ADOCIA Announces Its Participation at Upcoming Investor Conferences in 2025 Icon check
12/12/2024 ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment Icon check
10/30/2024 ADOCIA Reports Third Quarter 2024 Financial Results and Provides a Business Update Icon check
10/15/2024 ADOCIA announces patenting stable combinations of GLP-1 and amylin analogs for the treatment of obesity and diabetes using its BioChaperone® platform Icon check
09/23/2024 ADOCIA Announces Appointment of Mathieu William Gilbert as Chief Financial Officer Icon check
09/19/2024 ADOCIA Announces First Half 2024 Financial Results and Provides a Business Update Icon check
08/29/2024 ADOCIA to Deliver Oral Presentations on AdoShell® and AdoGel® at EASD Annual Meeting Icon check
07/24/2024 ADOCIA Reports Second Quarter 2024 Financial Results and Provides a Business Update Icon check
07/10/2024 ADOCIA Announces that Tonghua Dongbao is Discontinuing one of the two Partnership Programs: BioChaperone® Combo Icon check
06/18/2024 ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions Icon check
06/03/2024 ADOCIA Announces Appointment of Mathieu William Gilbert as Chief Operating Officer Icon check
05/23/2024 ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 13th, 2024 in Paris Icon check
05/14/2024 ADOCIA Reports First Quarter 2024 Financial Results and Provides a Business Update Icon check
04/29/2024 ADOCIA Announces the Release of its Universal Registration Document for the Year 2023 Icon check
04/24/2024 ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial Update Icon check
03/21/2024 ADOCIA Announces a €2 Million Fundraising from its two Main Shareholders and a Member of its Management, and the Signature of an Equity Financing Line with Vester Finance Icon check
03/06/2024 ADOCIA Announces Its Participation at Key Events Icon check
02/27/2024 ADOCIA Reports Fourth Quarter 2023 Financial Results and Provides a Business Update Icon check
01/25/2024 ADOCIA Announces its Financial Calendar for 2024 Icon check
11/23/2023 Letter to Shareholders – November 2023 Icon check
11/09/2023 ADOCIA Revealed Promising Preclinical Data on AdoShell® Islets for Cell Therapy of Diabetes Icon check
10/25/2023 ADOCIA Reports Financial Results of Third Quarter 2023 and Provides an Update on its Activities Icon check
10/23/2023 ADOCIA’s Partner Tonghua Dongbao Announces Positive Results of Three Clinical Trials on BioChaperone® Combo Icon check
09/25/2023 ADOCIA Announces Oral Presentations on AdoShell® Islets at EASD and IPITA-IXA-CTRMS Congresses Icon check
09/18/2023 ADOCIA Announces First Half 2023 Financial Results and Provides a Business Update Icon check
09/14/2023 Number of shares and voting rights of ADOCIA as of August 31st, 2023 Icon check
08/31/2023 ADOCIA Announces that it has Received €500.000 in Proceeds from a Partial Exercise of Warrants Held by IPF Partners Icon check
07/25/2023 ADOCIA announces Q2 2023 financial results and a €10 million financing operation Icon check
07/05/2023 ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing Icon check
06/01/2023 Listing of ADOCIA shares suspended Icon check
05/15/2023 ADOCIA Announces the Appointment of Olivier Soula as Chief Executive Officer Icon check
04/25/2023 ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities Icon check
04/20/2023 ADOCIA announces its annual Shareholders’ meeting to be held on May 11, 2023 in Paris Icon check
03/15/2023 ADOCIA announces its annual results for 2022 and provides corporate and financial update Icon check
01/30/2023 ADOCIA publishes its Letter to Shareholders Icon check
12/21/2022 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023 Icon check
12/01/2022 Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products Icon check
10/25/2022 ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates Icon check
10/06/2022 ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis Icon check
10/03/2022 ADOCIA: Upcoming investor meetings Icon check
09/19/2022 ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update Icon check
09/15/2022 ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th Icon check
09/07/2022 ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes Icon check
08/24/2022 ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update Icon check
06/23/2022 Adocia publishes its Letter to Shareholders Icon check
06/21/2022 ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes Icon check
05/20/2022 ADOCIA Announces its annual Shareholders’ meeting to be held on June 28, 2022 in Paris Icon check
05/18/2022 ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao Icon check
05/09/2022 ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao Icon check
04/19/2022 ADOCIA announces its annual results for 2021 and presents an update on activities Icon check
04/11/2022 ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao Icon check
03/28/2022 Adocia strengthens its cash position by 19 million euros following a real estate transaction Icon check
02/23/2022 ADOCIA announces 2021 fourth quarter financial results Icon check
01/11/2022 Number of shares and voting rights of ADOCIA as of December 31st, 2021 Icon check
01/06/2022 ADOCIA announces its financial calendar for 2022 Icon check
12/20/2021 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022 Icon check
12/13/2021 Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides Icon check
10/26/2021 Adocia announces 2021 third quarter financial results and a financing of €7 million Icon check
10/14/2021 ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China Icon check
09/21/2021 ADOCIA announces Oral Presentation Reviewing M1Pram (ADO09) at the occasion of the 57th Annual Meeting of EASD Icon check
Join our mailing list. Subscribe